Total medical devices industry M&A deals in Q1 2020 worth $13.89bn were announced globally, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
The value marked an increase of 60.4% over the previous quarter and a rise of 39.4% when compared with the last four-quarter average, which stood at $9.96bn.
Comparing deals value in different regions of the globe, Europe held the top position, with total announced deals in the period worth $11.8bn. At the country level, The Netherlands topped the list in terms of deal value at $11.5bn.
In terms of volumes, North America emerged as the top region for medical devices industry M&A deals globally, followed by Europe and then Asia-Pacific.
The top country in terms of M&A deals activity in Q1 2020 was the US with 55 deals, followed by France with six and the UK with five.
In 2020, as of the end of Q1 2020, medical devices M&A deals worth $13.89bn were announced globally, marking an increase of 63.02% year on year.
Medical devices industry M&A deals in Q1 2020: Top deals
The top five medical devices industry M&A deals accounted for 94.02% of the overall value during Q1 2020.
The combined value of the top five medical devices M&A deals stood at $13.06bn, against the overall value of $13.89bn recorded for the month.
The top five medical devices industry deals of Q1 2020 tracked by GlobalData were:
1) Thermo Fisher Scientific’s $11.5bn acquisition of Qiagen
2) The $1.1bn acquisition of Dermira by Eli Lilly and
3) Dezhan Health’s $239.55m acquisition of Beijing Changjiangmai MedicalTechnology Co., Ltd.
4) The $121.9m acquisition of EOS imaging by Alphatec Holdings
5) Anika Therapeutics’ acquisition of ArthroSurface for $100m.
Verdict deals analysis methodology
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.